Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.
about
Progress of small molecular inhibitors in the development of anti-influenza virus agents.Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work.Filling gaps in PPAR-alpha signaling through comparative nutrigenomics analysis.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza.Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Circadian rhythm of clock genes in human adipose explantsHepatic circadian clock oscillators and nuclear receptors integrate microbiome-derived signals.Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology.Inhibitors of Fatty Acid Synthesis Induce PPAR α -Regulated Fatty Acid β -Oxidative Genes: Synergistic Roles of L-FABP and GlucoseUpdate on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults.Fenofibrate in the treatment of dyslipidemia associated with HIV infection.Lipid-lowering effects of ezetimibe and simvastatin in combination.Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke.Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemiaStatin islands and PPAR ligands in platelets.Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.Changes in PPAR gene expression and myocardial tolerance to ischaemia: relevance to pleiotropic effects of statins.PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke.Report of the 'mechanisms of lung injury and immunomodulator interventions in influenza' workshop, 21 March 2010, Ventura, California, USA.
P2860
Q30234943-3E638C27-F4F7-4B81-A2CC-F5A81A53E80EQ30379206-5DC06E66-E676-491A-93E6-EF60787025CDQ33517939-805CF9B4-3E19-49D7-9EEA-A230195FDC0AQ33577851-81D929C8-30CE-4F61-AF8E-C15DCA843DD3Q33941922-7F21D283-F79F-4E98-B4A7-12D12A0D3FD4Q34662589-C3B97D5B-364C-4C29-B3A1-92E8A92126E5Q35600920-DEF9D8B8-226D-4B61-AC3C-AEBFEB5AD30BQ35924335-E0A19865-BAAB-485D-8446-F653865288E5Q36072867-C3F43193-64FB-4C34-BA69-F75D69BDB3D9Q36692326-93954D7A-3D95-44B9-8F3A-E8D2DFF634E4Q37019924-46303B49-EE22-4DAA-BA71-1223EB57A08AQ37139485-0FD928ED-446A-45F7-B96D-95893683D4AAQ37770249-808CA97C-D8DD-4D4D-B3E2-BEA5BAB06A30Q37859778-9D80C3D2-AE04-4169-8474-DA6A28907F06Q38014975-EE036D28-5334-4EB5-9C28-EB1DD99B6B3BQ39173496-90A93953-A472-4995-BE01-E07851148402Q40625919-750A9EBF-356D-412D-B3D7-7350BDA178E0Q42557418-B83A3118-A8DA-4D81-A91F-14B23D6756B8Q42997897-0D29C24F-2953-4143-AB62-3C555325D7BBQ43211132-1BF19FAC-1DF1-430A-89E7-7085148AD869Q43860514-EBB13FD9-D7C9-4AD5-9CE0-009129D1C4A9Q46139825-4B73A678-BE25-4BA7-B466-43E090645D08
P2860
Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cross-talk between statins and ...... evidence and basic mechanisms.
@en
Cross-talk between statins and ...... evidence and basic mechanisms.
@nl
type
label
Cross-talk between statins and ...... evidence and basic mechanisms.
@en
Cross-talk between statins and ...... evidence and basic mechanisms.
@nl
prefLabel
Cross-talk between statins and ...... evidence and basic mechanisms.
@en
Cross-talk between statins and ...... evidence and basic mechanisms.
@nl
P1476
Cross-talk between statins and ...... evidence and basic mechanisms.
@en
P356
10.1016/J.TCM.2008.01.001
P577
2008-04-01T00:00:00Z